Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1

NCT06744504 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

AML
RUNX1-RUNX1T1 Fusion Protein Expression

Interventions

DRUG: cytarabine
DRUG: daunorubicin
DRUG: idarubicin
DRUG: cyclophosphamide

Sponsor

Institute of Hematology & Blood Diseases Hospital, China